KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Receivables (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Receivables for 16 consecutive years, with $9.8 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Receivables changed 0.4% year-over-year to $9.8 billion, compared with a TTM value of $9.8 billion through Sep 2024, changed 0.4%, and an annual FY2023 reading of $9.7 billion, up 2.51% over the prior year.
  • Receivables was $9.8 billion for Q3 2024 at Thermo Fisher Scientific, up from $9.4 billion in the prior quarter.
  • Across five years, Receivables topped out at $9.8 billion in Q3 2023 and bottomed at $5.2 billion in Q2 2020.
  • Average Receivables over 5 years is $8.1 billion, with a median of $8.9 billion recorded in 2021.
  • The sharpest move saw Receivables surged 41.59% in 2022, then decreased 0.59% in 2024.
  • Year by year, Receivables stood at $6.5 billion in 2020, then soared by 38.21% to $8.9 billion in 2021, then rose by 5.39% to $9.4 billion in 2022, then increased by 2.51% to $9.7 billion in 2023, then increased by 1.37% to $9.8 billion in 2024.
  • Business Quant data shows Receivables for TMO at $9.8 billion in Q3 2024, $9.4 billion in Q2 2024, and $9.4 billion in Q1 2024.